Impact of tenofovir versus abacavir on HIV-related endothelial dysfunction

AIDS Patient Care and STDs

Volumn 25, Issue 10, 2011, Pages 567-569

  Francisci, Daniela ^a   Falcinelli, Emanuela ^a   Belfiori, Barbara ^a   Petito, Eleonora ^a   Fierro, Tiziana ^a   Baldelli, Franco ^a   Gresele, Paolo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; MONOCYTE CHEMOTACTIC PROTEIN 1; TENOFOVIR; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ANTIVIRAL THERAPY; CASE CONTROL STUDY; CIRCULATING ENDOTHELIAL CELL; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MALE; RETROSPECTIVE STUDY;

ADENINE; ADULT; ANTI-HIV AGENTS; CASE-CONTROL STUDIES; CHEMOKINE CCL2; DIDEOXYNUCLEOSIDES; ENDOTHELIUM, VASCULAR; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MIDDLE AGED; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; VASCULAR CELL ADHESION MOLECULE-1; VASODILATION;

EID: 80053410662     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2011.0184     Document Type: Letter

References (13)

1. Choi AI, Vittinghoff E, Deeks SG, Weekley CC, Li Y, Shlipak MG. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS 2011;25:1289-1298.
2. Baker JV, Lundgren JD. Cardiovascular implications from untreated human immunodeficiency virus infection. Eur Heart J 2011;32:945-951.
3. Bernal E, Marín I, Muñ oz A, Sabán J, Vicente-Vera T, Cano A. High prevalence of subclinical atherosclerotic disease in Spanish HIV-infected patients with low cardiovascular risk. AIDS Patient Care STDs 2011;25:269-272.
4. Costagliola D, Lang S, Mary-Krause M, Boccara, F. Abacavir and cardiovascular risk: Reviewing the evidence. Curr HIV/ AIDS Rep 2010;7:127-133.
5. Durand M, Sheehy O, Baril JG, Lelorier J, Tremblay CL. Association between HIV infection, antiretroviral therapy and risk of acute myocardial infarction: A cohort and nested case-control study using Québec's public health insurance database (RAMQ). J Acquir Immune Defic Syndr (in press).
6. Reriani MK, Lerman LO, Lerman A. Endothelial function as a functional expression of cardiovascular risk factors. Biomark Med 2010;4:351-360.
7. Gresele P, Momi S, Migliacci R. Endothelium, venous thromboembolism and ischaemic cardiovascular events. Thromb Haemost 2010;103:56-61.
8. Francisci D, Giannini S, Baldelli F, et al. HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction. AIDS 2009;23:589-596.
9. Rubinshtein R, Kuvin JT, Soffler M, et al. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur Heart J 2010;31:1142-1148.
10. Gresele P, Migliacci R, Vedovati MC, et al. Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function. Thromb Res 2009;123:444-451.
11. Mariucci S, Rovati B, Bencardino K, Manzoni M, Danova M. Flow cytometric detection of circulating endothelial cells and endothelial progenitor cells in healthy subjects. Int J Lab Hematol 2010;32:e40-48.
12. Boos CJ, Lip GY, Blann AD. Circulating endothelial cells in cardiovascular disease. J Am Coll Cardiol 2006;48:1538-1547. (Pubitemid 44550075)
13. Melchjorsen J, Risør MW, Søgaard OS, et al. Tenofovir selectively regulates production of inflammatory cytokines and shifts the IL-12/IL-10 balance in human primary cells. J Acquir Immune Defic Syndr (in press).